Symbol="ERYP"
AssetType="Common Stock"
Name="Erytech Pharma SA ADR"
Description="ERYTECH Pharma SA, a clinical-stage biopharmaceutical company, develops red blood cell-based therapies for cancer and orphan diseases in France and the United States. The company is headquartered in Lyon, France."
CIK="1624422"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="60 AVENUE ROCKEFELLER, BATIMENT ADENINE, LYON, FR"
FiscalYearEnd="December"
LatestQuarter="2022-12-31"
MarketCapitalization="47399700"
EBITDA="-24972000"
PERatio="None"
PEGRatio="None"
BookValue="0.757"
DividendPerShare="0"
DividendYield="0"
EPS="-0.01"
RevenuePerShareTTM="0.214"
ProfitMargin="-0.0343"
OperatingMarginTTM="-4.084"
ReturnOnAssetsTTM="-0.301"
ReturnOnEquityTTM="-0.0098"
RevenueTTM="6647000"
GrossProfitTTM="4180000"
DilutedEPSTTM="-0.01"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="5.71"
AnalystTargetPrice="2.96"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="7.58"
PriceToBookRatio="0.654"
EVToRevenue="-"
EVToEBITDA="2.628"
Beta="2.129"
num_52WeekHigh="1.472"
num_52WeekLow="0.3"
num_50DayMovingAverage="0.859"
num_200DayMovingAverage="0.743"
SharesOutstanding="60749000"
DividendDate="None"
ExDividendDate="None"
symbol="ERYP"
open="0.70"
high="0.70"
low="0.70"
price="0.70"
volume="984.00"
latest_trading_day="2023-07-21"
previous_close="0.71"
change="-0.01"
change_percent="-1.4085%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="14"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="86"
Volume_recent_avg="93221"
Change_recent_avg="0.01"
Delta_recent_avg="0.08"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="0.29"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="86"
Aroon_momentum_negative="14"
image_negative_thumbnail_id_1="1102"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0135.jpeg"
image_negative_thumbnail_id_2="487"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0118.jpeg"
image_neutral_thumbnail_id_1="572"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0027.jpeg"
image_neutral_thumbnail_id_2="575"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_positive_thumbnail_id_1="1166"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Negative_0187.jpeg"
image_positive_thumbnail_id_2="696"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0012.jpeg"
image_professor_thumbnail_id_1="1185"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
image_professor_thumbnail_id_2="1188"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
